Ritholtz Wealth Management Sells 11,283 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Ritholtz Wealth Management cut its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 51.8% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 10,508 shares of the company’s stock after selling 11,283 shares during the period. Ritholtz Wealth Management’s holdings in Teva Pharmaceutical Industries were worth $176,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in TEVA. Harel Insurance Investments & Financial Services Ltd. lifted its position in Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company’s stock valued at $338,989,000 after acquiring an additional 22,044,407 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Teva Pharmaceutical Industries by 472.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company’s stock valued at $96,078,000 after acquiring an additional 5,186,592 shares in the last quarter. Nuveen LLC bought a new position in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $40,827,000. Assenagon Asset Management S.A. lifted its position in Teva Pharmaceutical Industries by 41.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 8,445,992 shares of the company’s stock valued at $141,555,000 after acquiring an additional 2,462,064 shares in the last quarter. Finally, Ion Asset Management Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 6.5% during the 1st quarter. Ion Asset Management Ltd. now owns 39,033,500 shares of the company’s stock valued at $599,945,000 after buying an additional 2,383,500 shares during the period. 54.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Placid Jover sold 6,053 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares of the company’s stock, valued at $102,693.84. The trade was a 47.19% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock opened at $19.01 on Wednesday. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80. The stock’s fifty day moving average is $19.00 and its 200 day moving average is $17.18. The stock has a market cap of $21.80 billion, a P/E ratio of -118.78, a P/E/G ratio of 1.07 and a beta of 0.71. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company had revenue of $4.18 billion for the quarter, compared to analysts’ expectations of $4.34 billion. During the same period last year, the firm earned $0.61 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was up .3% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on TEVA shares. UBS Group increased their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Wall Street Zen raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an “overweight” rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $25.57.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.